Haermonics is a clinical-stage medtech company focused on preventing postoperative complications in heart surgery patients. The company has developed an innovative flush therapy designed to eliminate residual blood and clots in the pericardial cavity, which are common causes of postoperative complications. This solution, created by a leading heart surgeon, aims to improve patient recovery and quality of life while reducing hospital and infrastructure costs. Haermonics serves hospitals and heart surgery centers, operating in the medical technology market. The business model is based on selling its patented flush therapy devices to healthcare providers. Revenue is generated through the sale of these devices, which have already shown promising results in clinical trials, including a 59% reduction in blood loss and zero reoperations. The company is preparing for a market launch, backed by extensive testing and clinical validation.

Keywords: medtech, heart surgery, flush therapy, postoperative care, clinical trials, patented design, healthcare providers, blood loss reduction, hospital cost savings, patient recovery.